Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study.

Canonica, Giorgio Walter; Colombo, Giorgio Lorenzo; Rogliani, Paola; Santus, Pierachille; Pitotti, Claudia; Di Matteo, Sergio; Martinotti, Chiara; Bruno, Giacomo Matteo

Canonica, Giorgio Walter; Colombo, Giorgio Lorenzo; Rogliani, Paola; Santus, Pierachille; Pitotti, Claudia; Di Matteo, Sergio; Martinotti, Chiara; Bruno, Giacomo Matteo.

Afiliação

Canonica GW; Asthma & Allergy Clinic, Humanitas University, Milan, Italy.
Colombo GL; S.A.V.E. S.r.l. Studi Analisi Valutazioni Economiche Health Economics & Outcomes Research - Research Center, Milan, Italy.
Rogliani P; Drug Science Department, Pavia University, Pavia, Italy.
Santus P; Respiratory Unit, Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy.
Pitotti C; Department of Biomedical and Clinical Sciences (DIBIC), University of Milan, Division of Pulmonary Diseases, Ospedale L. Sacco, ASST Fatebenefratelli-Sacco, Milan, Italy.
Di Matteo S; Novartis Farma S.p.A, Milan, Italy.
Martinotti C; Drug Science Department, Pavia University, Pavia, Italy.
Bruno GM; Drug Science Department, Pavia University, Pavia, Italy.

Risk Manag Healthc Policy ; 13: 43-53, 2020.

Article em En | MEDLINE | ID: mdl-32158289

Palavras-chave

PROXIMA study; cost-utility; effectiveness; healthcare costs; omalizumab; severe allergic asthma

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation Idioma: En Revista: Risk Manag Healthc Policy Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Itália

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google